Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

Leukemia. 2014 Feb;28(2):404-7. doi: 10.1038/leu.2013.205. Epub 2013 Jul 4.

Authors

T Zhou¹, S Georgeon², R Moser³, D J Moore³, A Caflisch¹, O Hantschel²

Affiliations

¹ Department of Biochemistry, University of Zürich, Zürich, Switzerland.
² Swiss Institute for Experimental Cancer Research, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.
³ Brain Mind Institute, School of Life Sciences, École polytechnique fédérale de Lausanne, Lausanne, Switzerland.

PMID: 23823659
DOI: 10.1038/leu.2013.205

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Janus Kinase 2 / antagonists & inhibitors
Janus Kinase 2 / chemistry*
Models, Molecular
Molecular Conformation
Protein Binding
Protein Kinase Inhibitors / chemistry*
Protein Kinase Inhibitors / pharmacology
Pyrrolidines / chemistry*
Pyrrolidines / pharmacology
Sulfonamides / chemistry*
Sulfonamides / pharmacology

Substances

Protein Kinase Inhibitors
Pyrrolidines
Sulfonamides
fedratinib
Janus Kinase 2